Navigation Links
Micromet to Present at the Susquehanna Financial Group's SIGnificant Investment Options Conference on March 4, 2008
Date:2/29/2008

BETHESDA, Md., Feb. 29 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that Dr. Christian Itin, President and Chief Executive Officer of Micromet, will present at the Susquehanna Financial Group's SIGnificant Investment Options Conference on Tuesday, March 4, 2008, at 10:30 am ET at the W Hotel in New York.

Dr. Itin's presentation will be available on Micromet's website at http://www.micromet-inc.com following the event.

About Micromet, Inc. (http://www.micromet-inc.com)

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Three of its antibodies are in clinical development. MT103 (MEDI-538), the most advanced antibody in Micromet's product pipeline developed using the BiTE(R) antibody technology platform, is being developed in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia, and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells to eliminate cancer cells. Micromet is developing MT103 in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. The second clinical stage antibody is adecatumumab (MT201), a human monoclonal antibody targeting EpCAM-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The third clinical stage antibody is MT293 (TRC093), a first-in-class humanized monoclonal antibody that inhibits angiogenesis and tumor cell growth by binding cleaved collagen. MT293 is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer and age-related macular degeneration. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, Micromet's human antibody neutralizing the activity of GM-CSF, which has potential applications in the treatment of inflammatory diseases, such as rheumatoid arthritis, as well as autoimmune diseases.


'/>"/>
SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Micromet to Present at Two Upcoming Investor Conferences
2. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
3. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
4. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
5. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
6. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
7. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
8. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
9. NPS Pharmaceuticals to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
10. Kendle to Present at the 29th Annual Raymond James Institutional Investors Conference
11. Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2020)... ... May 04, 2020 , ... ... for the life sciences industry, today announced that Informa Training Partners, a life ... its name to Red Nucleus Boston, effective immediately. , “The name change solidifies ...
(Date:4/26/2020)... ... April 23, 2020 , ... Indegene ... online store providing applications and services for use on Microsoft Azure. The customer ... to sign up online for a built-for-purpose customer engagement capability to use in ...
(Date:4/22/2020)... ... April 21, 2020 , ... Ripple Science today announced ... trial teams are working remotely and have paused patient visits, forcing teams to ... their research during this uncertain time by giving research teams free access to ...
(Date:4/1/2020)... Ky. (PRWEB) , ... March 30, 2020 , ... ... launch of its latest product, ArmourGuard® RTU, an EPA-approved spray-on antimicrobial solution. As ... only biosecurity solution that provides continual antimicrobial activity against microorganisms for up to ...
Breaking Biology Technology:
(Date:5/14/2020)... ... 13, 2020 , ... DuPont Nutrition & Biosciences (DuPont) today ... dairy market. This unique product allows for process optimization and cost reduction, enabling ... across North America. , Among the numerous benefits Bonlacta™ offers, it is fast ...
(Date:5/6/2020)... ... May 06, 2020 , ... ... http://www.brevitest.com ) will become the latest out-of-state company to partner with ... Harbor. , Brevitest has developed a point-of-care analyzer capable of accurately performing ...
(Date:5/1/2020)... ... May 01, 2020 , ... More than 600 people undergo ... High-Risk Cancer Program, which is led by two genetic counselors. , My Gene ... it is teaming up with UConn’s High Rick Program to ensure that UConn’s patients ...
Breaking Biology News(10 mins):